You are here

SARC003

Completed
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Type of Sarcoma: 
Recurrent Ewing’s Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma
Drug: 
Gemcitabine and Docetaxel
Accrual Status: 
Completed
Co-Principal Investigators: 

Elizabeth Fox, MD
National Cancer Institute
 
Shreyaskumar Patel, MD
MD Anderson Cancer Center

For more information about this trial and open sites: